Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by


Editors' pick

18-07-2018 | Pancreatic cancer | News

Four-drug chemotherapy regimen for metastatic PDAC warrants further investigation

The PAXG regimen comprising cisplatin, nab-paclitaxel, capecitabine, and gemcitabine shows promising efficacy and tolerability relative to the standard combination of nab-paclitaxel plus gemcitabine in chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma, say the PACT-19 investigators.

Source:

Lancet Gastroenterol Hepatol 2018; doi:10.1016/S2468-1253(18)30196-1

Latest headlines

19-07-2018 | FDA | News

Enzalutamide receives FDA approval for nonmetastatic CRPC

Find out more here

18-07-2018 | Pancreatic cancer | News

Four-drug chemotherapy regimen for metastatic PDAC warrants further investigation

The PAXG regimen comprising cisplatin, nab-paclitaxel, capecitabine, and gemcitabine shows promising efficacy and tolerability relative to the standard combination of nab-paclitaxel plus gemcitabine in chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma, say the PACT-19 investigators.

17-07-2018 | Survival | News

Alcohol use, physical inactivity after cancer diagnosis linked to poor survival

US researchers stress the need for effective interventions to reduce alcohol use and increase physical activity in patients with advanced cancer.

In depth

27-04-2018 | Adolescents and young adults | Feature | Article

ACCELERATE-ing access to drugs for adolescents with cancer

medwireNews spoke to Miranda Fidler, from the International Agency for Research on Cancer, and Simon Davies, from Teen Cancer America, about the ACCELERATE working group's proposal to improve adolescent patients’ access to new cancer drugs.

Click for the accompanying news story

SUMIT: Selumetinib in metastatic uveal melanoma

This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

Expert comment: AMPLE trial

Listen to Fabien Maldonado, from Vanderbilt University Medical Center in Nashville, Tennessee, USA, give his views on the AMPLE trial, published in JAMA, which aimed to establish the more effective technique for reducing the number of hospitalization days in patients with malignant pleural effusion.

image credits